Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference121 articles.
1. Drug discovery in advanced prostate cancer: translating biology into therapy;Yap;Nat. Rev. Drug Discov.,2016
2. Recent advances in prostate cancer treatment and drug discovery;Nevedomskaya;Int. J. Mol. Sci.,2018
3. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group;Lancet,1995
4. Characterising the castration-resistant prostate cancer population: a systematic review;Kirby;Int. J. Clin. Pract.,2011
5. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences;Chang;Br. J. Cancer,2014
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SWI/SNF chromatin remodelers in prostate cancer progression;Frontiers in Epigenetics and Epigenomics;2024-01-04
2. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants;Cells;2024-01-04
3. Exploring inhibitory components of Hedyotis diffusa on androgen receptor through molecular docking and molecular dynamics simulations;Medicine;2023-12-29
4. Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives;Biomedicine & Pharmacotherapy;2023-12
5. Synthesis and Evaluation of Small Molecule Inhibitors of the Androgen Receptor N-Terminal Domain;ACS Medicinal Chemistry Letters;2023-11-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3